AI주식인사이트AI Stock Insight
C

동화약품

000020KOSPI의약품 제조업

47.6 / 100

Reference Date: 2026-06-10

Financial Score15.5 / 40
News Sentiment17.1 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Declined 9.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongwha Pharm operates in pharmaceuticals, medical device manufacturing and sales, and other financial services. In 2023, sales increased by 6.78% to 496,394 million won compared to the previous year, but operating profit fell by 98.09%. Key subsidiaries include Medissei (medical device manufacturer), TS Care (Vietnam-based pharmaceutical distribution chain), and Dongwha Kripton (venture investment firm).

Number of Employees

838people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
38.96Industry Average 11.930.0Point

3.3x industry avg (risky)

PBR
0.37Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
0.96Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
9.44Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲17.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.9% (declining, 3yr)

Detailed News Sentiment

17 totalPositive 10Neutral 7Negative 0Average Sentiment Score 68.5

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 5,360Won52-week high 7,06052-week low 5,360
1-month return1.0Point

1m -9.15% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15